Literature DB >> 28601708

Development of efficient docking strategies and structure-activity relationship study of the c-Met type II inhibitors.

Ming-Jing Li1, Guan-Zhao Wu1, Quentin Kaas2, Tao Jiang1, Ri-Lei Yu3.   

Abstract

c-Met is a transmembrane receptor tyrosine kinase and an important therapeutic target for anticancer drugs. In the present study, we systematically investigated the influence of a range of parameters on the correlation between experimental and calculated binding free energies of type II c-Met inhibitors. We especially focused on evaluating the impact of different force fields, binding energy calculation methods, docking protocols, conformation sampling strategies, and conformations of the binding site captured in several crystallographic structures. Our results suggest that the force fields, the protein flexibility, and the selected conformation of the binding site substantially influence the correlation coefficient, while the sampling strategies and ensemble docking only mildly affect the prediction accuracy. Structure-activity relationship study suggests that the structural determinants to the high binding affinity of the type II inhibitors originate from its overall linear shape, hydrophobicity, and two conserved hydrogen bonds. Results from this study will form the basis for establishing an efficient computational docking approach for c-Met type II inhibitors design.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Binding affinity; Computational screening; Conformation; Docking; Force field; c-Met

Mesh:

Substances:

Year:  2017        PMID: 28601708     DOI: 10.1016/j.jmgm.2017.04.004

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  1 in total

1.  Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors.

Authors:  Hehua Xiong; Jianxin Cheng; Jianqing Zhang; Qian Zhang; Zhen Xiao; Han Zhang; Qidong Tang; Pengwu Zheng
Journal:  Molecules       Date:  2019-12-18       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.